Research progress in antiviral therapy for decompensated hepatitis B cirrhosis

Decompensated hepatitis B cirrhosis is one of the final outcomes of chronic hepatitis B and liver fibrosis. Extensive studies have demonstrated that antiviral therapy can slow disease progression, improve clinical outcomes, reduce complications, slow decompensated cirrhosis progression, and improve survival. At present, nucleoside and nucleotide analogues are the most common antiviral agents in the treatment of decompensated hepatitis B cirrhosis. This paper introduces effective antiviral agents against decompensated hepatitis B cirrhosis and discusses potential problems in antiviral treatment, suggesting that personalized medication should be achieved on the basis of standardized antiviral treatment in clinical practice